Company Gyroscope Therapeutics Holdings plc
Equities
VISN
US40382N1037
Biotechnology & Medical Research
Business Summary
Number of employees: 179
Sales per Business
USD in Million | 2020 | Weight | Delta |
---|---|---|---|
Clinical - Stage Gene Therapy
100.0
%
| 1 | 100.0 % | - |
Sales per region
USD in Million | 2020 | Weight | Delta |
---|---|---|---|
United States
70.0
%
| 1 | 70.0 % | - |
United Kingdom
30.0
%
| 0 | 30.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ian Pitfield
CTO | Chief Tech/Sci/R&D Officer | 58 | 30/06/20 |
Jane Hughes
CTO | Chief Tech/Sci/R&D Officer | 50 | 30/09/19 |
Edward Lang
PRN | Corporate Officer/Principal | 44 | 31/05/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | - | |
Director/Board Member | 51 | - | |
Janet Hopkins
BRD | Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,229,659 | 28,937,362 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Gyroscope Therapeutics Holdings Plc
Gunnels Wood Road
SG1 2FX, Stevenage
+44 14 3890 6770
![address Gyroscope Therapeutics Holdings plc(VISN)](https://cdn.zonebourse.com/static/address/122418930.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |